Today: 3 April 2026
Subscribe
Browse Category

NYSE:CYTK 2 January 2026

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
2 January 2026
·

Stock Market Today

  • Aisin (TSE:7259) Seen Undervalued Amid Recent Share Price Decline
    April 3, 2026, 12:13 PM EDT. Aisin's shares have fallen about 8% in the last month and 23% over three months, signaling short-term weakness despite a 58% total return over the past year. Currently trading at ¥2,245.5, the stock's price-to-earnings (P/E) ratio stands at 9.8x, below peers' average of 17.4x and the auto components industry average of 10x, suggesting potential undervaluation. Analysts note the stock trades under an estimated fair P/E of 14.6x. However, the market may be pricing in future growth risks given a 54% intrinsic discount. A discounted cash flow (DCF) model values the stock at ¥4,894.59, more than double the current price, raising questions about long-term market expectations for Aisin, an auto parts leader.
Go toTop